Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 202Central Nervous System Neoplasms 122Brain Neoplasms 107Gliosarcoma 85Glioma 68Astrocytoma 63Oligodendroglioma 34Neuroblastoma 29Medulloblastoma 20Neoplasm Metastasis 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 14Ependymoma 11Diffuse Intrinsic Pontine Glioma 11Breast Neoplasms 11Meningeal Carcinomatosis 8Neoplasms 7Lymphoma 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Lymphoma, Follicular 6Head and Neck Neoplasms 6Esthesioneuroblastoma, Olfactory 6Burkitt Lymphoma 6Spinal Cord Neoplasms 5Salivary Gland Neoplasms 5Rhabdoid Tumor 5Recurrence 5

Interventions

Trastuzumab 2Radiotherapy 2Capecitabine 2tucatinib 1sapanisertib 1pertuzumab 1patritumab deruxtecan 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1fludarabine 1eribulin 1avelumab 1WP 744 1Temozolomide 1Spinal Puncture 1Rituximab 1Psychiatric Rehabilitation 1Phlebotomy 1Methotrexate 1Cyclophosphamide 1Amplified Fragment Length Polymorphism Analysis 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Meningeal Neoplasms × Radiotherapy × CNS × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡